Image Analysis Group (IAG), a leader in clinical trial imaging and AI-based biomarkers, is bolstering its footprint in the United States with a new office in Cambridge, Massachusetts. This strategic location in the Boston area positions IAG closer to biotech and pharmaceutical companies, enhancing its ability to forge strong partnerships and offer localized support for clinical trials within the region.
The expansion marks a key development for IAG, which operates across various therapeutic fields, including oncology, neuro-oncology, radiopharmaceuticals, immunology, rheumatic diseases, and metabolic diseases. By establishing a presence in Cambridge, IAG aims to collaborate more effectively with sponsors and contract research organizations (CROs) involved in Phase I–III clinical trials and complex imaging programs.
Furthermore, the new office is set to create employment opportunities in the local market, with plans to hire personnel in areas such as clinical imaging operations, data science, regulatory support, and business development over the next 12 to 24 months. This move will fortify IAG’s comprehensive imaging services, which encompass clinical trial design consultation, imaging protocol optimization, centralized image analysis, and regulatory-compliant data delivery.
As part of the thriving Boston life-sciences ecosystem, IAG anticipates better collaboration with biotechnology firms, pharmaceutical companies, academic institutions, and clinical research centers. Globally, IAG’s operations span North America, Europe, and the Asia-Pacific, working with entities across the pharmaceutical, biotechnology, and medtech sectors to ensure consistency in imaging protocols and data analysis for multi-center studies.
Founded in 2007 and headquartered in London, IAG operates as an imaging Clinical Research Organization (iCRO). It supports various industry players with imaging-based clinical trial endpoints through its DYNAMIKA™ platform, which integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time oversight of clinical trials.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.